PCM
UTHR icon

Penserra Capital Management’s United Therapeutics UTHR Stock Holding History

Penserra Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,772
Closed -$883K – 1322
2024
Q2 		$883K Buy
+2,772
New +$734K 0.01% 455
2022
Q3 		– Sell
-2,540
Closed -$598K – 1217
2022
Q2 		$598K Buy
+2,540
New +$516K 0.02% 444
2020
Q4 		– Sell
-380
Closed -$38K – 1130
2020
Q3 		$38K Buy
+380
New +$41.7K ﹤0.01% 664

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Penserra Capital Management's UTHR Position: Q3 2024 in Review

Penserra Capital Management sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 2,772 shares — an estimated $883K sold.

Penserra Capital Management first reported a position in UTHR in Q3 2020 and held it in 3 quarters. The position peaked at $883K in Q2 2024. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • Penserra Capital Management reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Penserra Capital Management sold 2,772 United Therapeutics shares in Q3 2024, an estimated $883K.
  • Penserra Capital Management first reported a position in United Therapeutics in Q3 2020 and held it in 3 quarters.
  • Penserra Capital Management's United Therapeutics position peaked at $883K in Q2 2024.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Penserra Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.